Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

The Iowa Senate bill alters a proposal that would have penalized administering gene-based vaccines including the COVID-19 ...

Researchers at the Wuhan Institute of Virology in China said they discovered a new coronavirus in bats that enters cells ...

Novavax’s COVID-19 vaccine produced higher ... used target for the other vaccines in development against COVID-19. It works by causing the body to produce antibodies that can bind to the Spike ...

Late last week in Morbidity and Mortality Weekly Report, authors from the Centers for Disease Control and Prevention (CDC) ...

HHS Assistant Secretary of Public Affairs Tom Corry unexpectedly stepped down on Feb. 28. In a brief post on X Monday morning ...

The split will allow WBD to take advantage of "broader market opportunities" as they arise, CEO David Zaslav told analysts.

Novavax reported Q4 sales of $88.31 million, beating estimates despite a decline. The company shifts focus to partnerships ...